Precision medicine reporting solutions company GenomOncology (GO) announced on Wednesday that it has formed a strategic partnership with Oregon Health & Science University's (OHSU) Knight Diagnostics Lab (KDL) to enhance clinical trial matching for cancer patients.

KDL will implement GO's Clinical Trials Matching Solution to streamline the identification of relevant precision oncology trials and improve patient access to trials and treatment options.

The GO Clinical Trials Matching Solution will integrate directly into KDL's decision support workflow, automatically matching patients to open trials based on their unique molecular profiles and clinical characteristics. The system offers comprehensive trial information including phase, title, locations, sponsor details, and eligibility criteria. The solution delivers transparent explanations of why each trial, including trial arms, matched a patient's clinical status, enabling pathologists and the multidisciplinary team to make informed recommendations with confidence.

Garreth Hippe, chief commercial officer of GenomOncology, said: "Access to clinical trials remains a significant barrier in cancer care, with many patients never learning about trials that could benefit them. Our partnership with OHSU's Knight Diagnostics Lab demonstrates how intelligent automation can break down these barriers. By embedding clinical trial matching directly into the diagnostic workflow, we're ensuring that every patient receives personalised trial options at the moment they matter most."